Gross Profit Trends Compared: AbbVie Inc. vs Teva Pharmaceutical Industries Limited

Pharma Giants' Profit Trends: AbbVie vs Teva

__timestampAbbVie Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20141553400000011056000000
Thursday, January 1, 20151835900000011356000000
Friday, January 1, 20161980500000011859000000
Sunday, January 1, 20172117600000010825000000
Monday, January 1, 2018250350000008296000000
Tuesday, January 1, 2019258270000007536000000
Wednesday, January 1, 2020304170000007725000000
Friday, January 1, 2021387510000007594000000
Saturday, January 1, 2022406400000006973000000
Sunday, January 1, 2023339030000007646000000
Monday, January 1, 2024394300000008064000000
Loading chart...

Unleashing insights

Gross Profit Trends: AbbVie Inc. vs Teva Pharmaceutical

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of two giants: AbbVie Inc. and Teva Pharmaceutical Industries Limited, from 2014 to 2023.

AbbVie Inc.

AbbVie has shown a remarkable upward trend, with gross profits increasing by approximately 118% over the decade. The peak was in 2022, with a slight dip in 2023, yet maintaining a robust position.

Teva Pharmaceutical

Conversely, Teva's gross profit has faced challenges, declining by around 30% since 2014. The most significant drop occurred between 2017 and 2018, reflecting industry pressures and strategic shifts.

Conclusion

This comparison highlights AbbVie's strong growth trajectory, contrasting with Teva's struggles. Investors and industry analysts can glean insights into strategic positioning and market dynamics from these trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025